Shares of Albany Molecular Research Inc. (NASDAQ:AMRI) were down 5.1% on Tuesday . The company traded as low as $13.97 and last traded at $13.97, with a volume of 88,665 shares. The stock had previously closed at $14.72.

Separately, Morgan Stanley reiterated a “buy” rating on shares of Albany Molecular Research in a research report on Sunday, May 8th.

The firm has a 50 day moving average price of $14.00 and a 200 day moving average price of $14.78. The company’s market cap is $488.23 million.

Albany Molecular Research (NASDAQ:AMRI) last released its quarterly earnings data on Tuesday, May 10th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.21 by $0.14. The business earned $102.80 million during the quarter, compared to the consensus estimate of $107.20 million. On average, equities analysts predict that Albany Molecular Research Inc. will post $1.05 earnings per share for the current fiscal year.

In other Albany Molecular Research news, SVP Steven R. Hagen sold 2,361 shares of Albany Molecular Research stock in a transaction that occurred on Friday, May 13th. The stock was sold at an average price of $12.77, for a total transaction of $30,149.97. Following the sale, the senior vice president now directly owns 37,564 shares of the company’s stock, valued at $479,692.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO George Svokos acquired 12,500 shares of the firm’s stock in a transaction on Friday, May 13th. The shares were bought at an average cost of $12.82 per share, for a total transaction of $160,250.00. Following the completion of the acquisition, the chief operating officer now directly owns 108,685 shares of the company’s stock, valued at approximately $1,393,341.70. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Albany Molecular Research stock. Mutual of America Capital Management LLC increased its position in shares of Albany Molecular Research Inc. (NASDAQ:AMRI) by 5.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 158,399 shares of the company’s stock after buying an additional 8,689 shares during the period. Mutual of America Capital Management LLC owned about 0.46% of Albany Molecular Research worth $3,144,000 as of its most recent SEC filing.

Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.